AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) Q3 2019 Earnings Conference Call - Final Transcript
Nov 01, 2019 • 08:00 am ET
Good morning. My name is Regina and I will be your conference operator today. At this time I would like to welcome everyone to the AMAG Pharmaceuticals Third Quarter 2019 Earnings Call. [Operator Instructions] It is now my pleasure to turn today's call over to Ms. Linda Lennox Vice President Investor Relations. You may begin your conference.
Linda S. Lennox
Thank you Regina. Good morning and welcome to the AMAG Pharmaceuticals conference call to discuss our third quarter financial results and corporate update. Earlier this morning we issued a press release. For those of you who don't have a copy you can access it in the Investors section of our website at amagpharma.com. Please be reminded that remarks made during this call may include forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We want to emphasize that these forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Please refer to our 2018 Form 10-K and our 2019 Form 10-Q as well as those included in our presentation materials for a full review of the risks and uncertainties associated with our business. On today's call we will discuss certain non-GAAP financial measures with respect to our performance.
We use these non-GAAP measures for financial and operational decision-making and as a means to evaluate our performance because we believe they better represent the ongoing economics of our business. The definitions of our non-GAAP measures are set forth in our earnings release which was filed with the SEC today. Copies may be obtained at sec.gov and in the Investors section of our website. We have forward-looking estimates of our long-term outlook. AMAG's growth trajectory and expectations for adjusted EBITDA on a multiyear time frame are based on a strategy of maximizing commercial product opportunities to fund investments in new products with various assumptions including certain assumptions about the progression and approval of AMAG's product candidates and the continued viability of AMAG's commercialized products including the Makena subcutaneous auto-injector. So please refer to these additional risk factors. With me on today's call are Bill Heiden our President and Chief Executive Officer; Dr. Julie Krop our Chief Medical Officer; Tony Casciano our Chief Commercial Officer; and Ted Myles our Chief Financial Officer. Let me quickly run through the agenda for this morning's call. Bill will briefly review the third quarter highlights.
Julie will discuss the recent Makena FDA Advisory Committee Meeting. Tony will provide an overview of our recent launch of Vyleesi. Ted will cover our third quarter financial results and our updated 2019 financial guidance. Julie will then come back to provide an update on our development programs. And Bill will provide some closing remarks and then open up the call for Q&A.
With that it's now my pleasure to turn the call over to Bill. Bill?
William K. Heiden
Thank you Linda. Good morning and thanks for joining us on our quarterly update call. In the third quarter we